Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multicenter North American Experience

BACKGROUND: Infliximab (IFX) infusion may lead to development of anti-IFX antibodies, and subsequent infusion reactions (IRs). The safety of rapid IFX infusion administered over 60 minutes has been under-investigated in children with inflammatory bowel disease. In a multicenter study, the frequency...

Full description

Saved in:
Bibliographic Details
Published in:Inflamm Bowel Dis
Main Authors: El-Matary, Wael, Dykes, Dana M. H., Bauman, Laura, Elkadri, Abdul, Carroll, Matthew W., Izaguirre, Marisa R., deBruyn, Jennifer, Samson, Charles M., Crim, Alisa Muniz, Ali, Sabina, Grossman, Andrew
Format: Artigo
Language:Inglês
Published: 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6551232/
https://ncbi.nlm.nih.gov/pubmed/29140940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MIB.0000000000001259
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items